Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — HC Wainwright Global Investment Conference 2022
18 slides from Kazia Therapeutics's conference presentation, Sep 15, 2022
Slide 1: A Diversified Oncology Drug Development Company
Exhibit 99.1 A Diversified Oncology Drug Development Company Presentation to HC Wainwright Global Investment Conference New York, NY 14 September 2022 ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All state
Slide 3: Company Overview
Company Overview A late-clinical-stage oncology drug development company Company is dual-listed on NASDAQ Paxalisib EVT801 (KZIA) and ASX (KZA) with market cap around US$ 30 million Brain-penetrant pan-PI3K / mTOR inhibitor Selective VEGFR3 inhibitor • Well-validated class with 5x FDA-approved thera
Slide 4: Pipeline
Pipeline Two world-class assets in clinical trials licensed from: Paxalisib (formerly GDC-0084) Small molecule, highly potent, brain-penetrant inhibitor of PI3K / mTOR PRECLIN. PHASE 1 PHASE 2 PHASE 3 MARKET Glioblastoma Most common primary brain cancer DIPG Highly aggressive childhood brain cancer
Slide 5: Paxalisib – Kazia's Lead Program
Paxalisib – Kazia’s Lead Program Multiple signals of clinical efficacy in brain tumors Glioblastoma Brain Metastases DIPG “dramatic reductions in tumor 15.7 months 100% volume and complete resolution of disease symptoms, extending overall survival overall response rate overall survival” in newly-dia
Slide 6: Operating Model
Operating Model In-licensing advanced assets drives earlier value realization A Proven Strategy Jun 2010 – licensed niraparib from Merck ® Mar 2017 – Zejula (niraparib) approved by FDA License under- Develop value Partner for Dec 2018 – Tesaro acquired by GSK valued assets through late-stage from la
Slide 7: Leadership
Leadership 160+ years of international drug development experience Board Management Team Iain Ross Dr James Garner Chairman Chief Executive Officer & Executive Director Executive and Board roles in pharma Physician / MBA; Extensive drug and small biotech development experience Bryce Carmine Dr John
Slide 8: Scientific Advisory Board
Scientific Advisory Board World-leading experts in brain cancer Priscilla K Brastianos, MD John de Groot, MD Alan Olivero, PhD Patrick Y Wen, MD Associate Professor of Medicine Division Chief, Neuro-Oncology Drug Development Consultant Professor of Neurology Harvard Medical School UCSF Harvard Medic
Slide 9: Paxalisib is one of the most broadly potent PI3K inhibitors in the global pipeline
Paxalisib is one of the most broadly potent PI3K inhibitors in the global pipeline Paxalisib Among Most Potent PI3K Inhibitors Growth factor receptors (e.g. EGFR, HER2) IC (nM) 50 Idealisib (Gilead) p110a p110b p110g p110d mTORC PI3K 1/2 Alpelisib (Novartis) Paxalisib 2 46 10 3 70 Idelalisib 820 565
Slide 10: The PI3K inhibitor class is well-established, but paxalisib is unique
The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier Zydelig Aliqopa Copiktra Piqray Ukoniq paxalisib (idelalisib) (copanlisib) (duvelisib) (alpelisib) (umbralasib) FDA Approved FDA Approved FDA Approved FDA Approved FDA Approved In pi
Slide 11: Phase II study of paxalisib mono-therapy in newly-diagnosed GBM
Phase II study of paxalisib mono-therapy in newly-diagnosed GBM provides robust signal of clinical efficacy Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Median PFS: 8.6 months (6.6-11.0) Median OS: 15.7 months (11.1-19.1) Comparator figure for existing therapy: 5.3 months Comp
Slide 12: Efficacy signal is corroborated by comparative reference data points
Efficacy signal is generally corroborated by comparison against multiple comparative reference data points Study Year n OS (95% CI) Applicability Comments Kazia Phase II Study 2022 30 15.7 (11.1-19.1) EORTC-NCIC Pivotal study that led to the approval of 2005 60 12.7 (11.6-14.4) Good Hegi et al. temo
Slide 13: Safety Profile in the phase II clinical study in GBM patients
Safety Profile in the phase 2 clinical study in GBM patients is generally mild to moderate, reversible, and manageable Number of Patients at Any Dose (n=30) Experiencing AEs ‘Possibly’ or ‘Likely’ Related to Paxalisib (affecting ≥10% of patients) Term Gr 1 Gr 2 Gr 3 Gr 4 Total (%) Fatigue 3 13 2 18
Slide 14: GBM AGILE international pivotal study is underway
GBM AGILE international pivotal study is underway Sponsored by GCAR with support of GBM key opinion leaders Key Points Regorafenib Bayer • A ‘platform study’, run independently of individual 3 Paxalisib companies, designed to expedite Kazia Therapeutics Economies of scale the approval of new drugs f
Slide 15: GBM AGILE was designed as a two-stage study
GBM AGILE was designed as a two-stage study; first stage may provide sufficient data for registration OVERALL STUDY DESIGN up to 150 patients 50 patients Stage 1 (‘Exploratory’) Stage 2 (‘Confirmatory’) Full FDA Approval Graduation Analysis POTENTIAL OUTCOMES FOR PAXALISIB, GIVEN DECISION IN AUGUST
Slide 16: Financial Metrics
as at 30 JUN 22 Financial Metrics Lean operating model drives financial efficiency Share Price (US$) 14.00 Market Capitalisation US$ 60M Listing 12.00 ASX (primary) KZA NASDAQ (ADSs @ 1:10 ratio) KZIA 10.00 Shares on Issue 138M NBI Average Daily Volume (12 months) $525,000 Nasdaq Biotech Index 8.00
Slide 17: CY2022 Milestones and Newsflow
CY2022 Milestones and Newsflow Multiple catalysts across two clinical programs Open GBM AGILE paxalisib arm to recruitment in EU 1H CY2022 ✓ Commence recruitment to paxalisib phase II GBM study at Weill Cornell 1H CY2022 ✓ Preclinical data for paxalisib in AT/RT presented at AACR (April 2022) 1H CY2
Slide 18: www.kaziatherapeutics.com [email protected]
www.kaziatherapeutics.com [email protected]
Kazia Therapeutics — HC Wainwright Global Investment Conference 2022 on 6ix